Simile is valued at $2 billion and has raised more than $300 million. Aaru carries a $1 billion headline price on about $88 million raised. Both are selling the same promise: ask a simulated population before you ask a real one.
Synthetic research, where AI agents stand in for survey panels and focus groups, produced two unicorn-priced startups in eight months. Aaru got there first, in December 2025. Simile came out of stealth in February 2026 and doubled Aaru's price by July. The two are now pitched to the same buyers: consumer brands, consultancies and financial firms that pay for market research. This comparison lines up what each has disclosed on valuation, capital, revenue, customers and method, and where each one fits.

Sources: TechCrunch (Dec 5, 2025 and Jul 30, 2026), Tech Funding News (Jul 31, 2026), Fortune (Jun 17, 2026), EY (Sep 30, 2026).
Aaru vs Simile: funding, valuation and customers side by side
In the Aaru vs Simile matchup, Simile leads on valuation ($2 billion against a $1 billion headline) and on capital raised (more than $300 million against about $88 million). Aaru leads on time in market, disclosed revenue and named enterprise distribution, including a September 2026 alliance with EY. Neither company has published audited revenue.
| Metric | Simile | Aaru |
|---|---|---|
| Latest valuation | $2B (Series B, Jul 30, 2026) | $1B headline, blended lower (Series A, Dec 2025) |
| Latest round | $200M Series B | $50M+ Series A |
| Lead investor | Greenoaks (B); Index Ventures (A) | Redpoint Ventures |
| Total raised | More than $300M | About $88M |
| Revenue disclosed | Not disclosed; grew 5x after Feb 2026 launch | ARR under $10M |
| Founded / launched | Public launch Feb 2026 (Stanford spinout) | Founded Mar 2024 |
| Named customers | CVS Health, Wealthfront, Deloitte, Gallup | EY, Accenture, IPG, McDonald's, Bayer, A24 |
| Distribution partner | CVS Health Ventures invested in Series B | EY alliance (Sep 30, 2026) |
| Team | 50+ people; Stanford co-founders | Founders were 15–19 at founding |
Sources: TechCrunch on Simile's Series B, Tech Funding News, TechCrunch on Aaru's Series A, Fortune. As of October 15, 2026.
Aaru vs Simile: Valuation and Capital Raised
TechCrunch, Tech Funding News and Fortune, Dec 2025 to Jul 2026
Simile has about 3.4x Aaru's capital (Value Add VC arithmetic); Aaru reached its $1 billion headline on less than a third of the money.
What is Aaru's valuation and revenue?
Aaru raised more than $50 million in a Series A led by Redpoint Ventures at a $1 billion "headline" valuation, TechCrunch reported on December 5, 2025. Some investors bought at $1 billion and others at a lower price, so the blended valuation sits below $1 billion. Earlier backers include A*, Abstract Ventures, Felicis, General Catalyst, Accenture Ventures and Z Fellows, and ARR was below $10 million at the time of the round.
Fortune's June 17, 2026 profile said Aaru had raised about $88 million and that ARR was still under $10 million; on those figures, the $1 billion headline is more than 100x revenue (Value Add VC arithmetic). Co-founders Cameron Fink, Ned Koh and John Kessler started the company in March 2024, when Kessler was 15. Koh's sales pitch, as Fortune quoted it: "Do not trust us. Do not trust our model."
The biggest commercial step since then is distribution. On September 30, 2026, EY announced an alliance with Aaru to sell behavioral simulation for marketing, pricing, sales and M&A decisions, starting in financial services. EY said Aaru replicated "six months of fieldwork, 3,600 investors and more than 30 markets in a single day" when tested against its 2025 Global Wealth Management study.
How much is Simile worth, and who backs it?
Simile is worth $2 billion after a $200 million Series B led by Greenoaks, TechCrunch reported on July 30, 2026, with Index Ventures, Hanabi, Bain Capital Ventures, A*, Factory, Definition and CVS Health Ventures participating. The round came five months after a $100 million Series A led by Index. Inshorts described the jump as 20-fold in five months; Simile has not confirmed its Series A price.
Simile's CEO is Joon Sung Park, whose Stanford dissertation included "Smallville," a project in which AI agents lived simulated human lives. His co-founders are Michael Bernstein, Percy Liang and Lainie Yallen, and the company has grown to more than 50 people, Tech Funding News reported. The same report said revenue grew fivefold after the February 2026 launch and that CVS Health, Wealthfront, Deloitte and Gallup use the platform. The full round history is in our Simile valuation breakdown.
How do Aaru and Simile differ in method?
Simile starts from real people. Its pitch is AI twins built from individual interviews and behavior, and its stated goal is "simulating all eight billion people on earth, accurately and honestly," per TechCrunch. That lineage makes it a natural fit for product and marketing research where a client wants to know how a defined customer segment reacts to a new offer.
Aaru starts from outcomes. TechCrunch describes a prediction model that "generates thousands of AI agents that simulate human behavior," and EY says the system is "trained directly on real-world behavioral outcomes." Aaru is best known for forecasts: Fortune reported that its New York mayoral simulation came within 2,000 votes of the final count, and that when EY's wealth survey showed 82% of clients saying they would stay with an advisor, against real-world retention of 20% to 30%, Aaru's rerun produced roughly 40%.
What the headline misses
Every accuracy claim in this category comes from the companies or their partners. Nate Silver argued on April 11, 2026 that synthetic samples "can't replace polls" because they produce no new data, noting that LLMs give too few "don't know" answers and too little variation between demographic groups; he also pointed to Aaru's 2024 model, which favored Harris in Michigan, Nevada, Pennsylvania and Wisconsin. Revenue is the other gap: Aaru's is small and Simile's is undisclosed, so both valuations price adoption that has not shown up in reported sales yet. One read on this: buyers will treat these tools as a fast first pass before real fieldwork, which supports a business but not every survey dollar.
Verdict: Aaru or Simile, by use case
- Financial services firm buying through a Big Four advisor: Aaru, via the EY alliance launched in September 2026.
- Consumer health or retail brand testing messages on defined customer segments: Simile, whose twins are built from real individuals and whose customers include CVS Health and Wealthfront.
- Forecasting a discrete outcome, such as an election or a churn rate: Aaru, which is built and marketed around outcome prediction.
- Investor betting on the better-capitalized platform: Simile, with more than 3x Aaru's capital and a research team behind the generative-agents work.
- Investor who wants disclosed traction per dollar of valuation: neither yet; Aaru's ARR is under $10 million and Simile's is not public.
Track both on the AI valuations dashboard and in our ranking of private AI companies by valuation.
Latest from the Pulse
Get VC data most people never see
— free to subscribe
Trace's notes on venture, AI and startups, a few times a week. Join 5,000+ subscribers. No spam.
No spam, unsubscribe anytime. Sent via Substack · Privacy · or subscribe on Substack ↗